<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="452">
  <stage>Registered</stage>
  <submitdate>3/06/2004</submitdate>
  <approvaldate>3/06/2004</approvaldate>
  <nctid>NCT00083889</nctid>
  <trial_identification>
    <studytitle>SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma</studytitle>
    <scientifictitle>A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>A6181034</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Carcinoma, Renal Cell</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Non melanoma skin cancer</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Kidney</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Interferon-alfa
Treatment: drugs - SU011248

Active Comparator: 2 - 

Experimental: 1 - 


Treatment: drugs: Interferon-alfa
3 MIU first week, 6 MIU second week, and 9 MIU thereafter three times a week (non-consecutive days) until progression or unacceptable toxicity

Treatment: drugs: SU011248
50 mg orally daily for 4 weeks and 2 weeks off treatment until progression or unacceptable toxicity

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression-Free Survival (PFS), Core Radiology Assessment</outcome>
      <timepoint>Day 28 of each 6-week cycle: duration of treatment phase</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Progression-Free Survival (PFS), Investigator's Assessment</outcome>
      <timepoint>Day 28 of each 6-week cycle: duration of treatment phase</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Objective Response, Core Radiology Assessment</outcome>
      <timepoint>Day 28 of each 6-week cycle: duration of treatment phase</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Objective Response, Investigator's Assessment</outcome>
      <timepoint>Day 28 of each 6-week cycle: duration of treatment phase</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS)</outcome>
      <timepoint>Clinic visit or telephone contact every 2 months until death</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Tumor Progression (TTP), Core Radiology Assessment</outcome>
      <timepoint>Randomization to first documentation of tumor progression: duration of treatment phase</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Tumor Progression (TTP), Investigator's Assessment</outcome>
      <timepoint>Randomization to first documentation of tumor progression: duration of treatment phase</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Response (DR), Core Radiology Assessement</outcome>
      <timepoint>Day 28 of each cycle: duraton of treatment phase</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Response (DR), Investigator's Assessment</outcome>
      <timepoint>Day 28 of each cycle: duration of treatment phase</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>FACT-Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) Subscale</outcome>
      <timepoint>Day 1 &amp; 28 of each cycle: duration of treatment phase</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>FACT-Kidney Symptom Index (FKSI) Subscale</outcome>
      <timepoint>Day 1 &amp; 28 of each cycle: duration of treatment phase</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Functional Assessment of Cancer Therapy-General (FACT-G)</outcome>
      <timepoint>Day 1 &amp; 28 of each cycle: duration of treatment phase</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Functional Assessment of Cancer Therapy-General (FACT-G): Physical Well Being (PWB) Subscale</outcome>
      <timepoint>Day 1 &amp; 28 of each cycle: duration of treatment phase</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Functional Assessment of Cancer Therapy-General (FACT-G): Social/Family Well Being (SWB) Subscale</outcome>
      <timepoint>Day 1 &amp; 28 of each cycle: duration of treatment phase</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Functional Assessment of Cancer Therapy-General (FACT-G): Emotional Well Being (EWB) Subscale</outcome>
      <timepoint>Day 1 &amp; 28 of each cycle: duration of treatment phase</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Functional Assessment of Cancer Therapy-General (FACT-G): Functional Well Being (FWB) Subscale</outcome>
      <timepoint>Day 1 &amp; 28 of each cycle: duration of treatment phase</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>EuroQoL Five Dimension (EQ-5D) Health State Index</outcome>
      <timepoint>Day 1 &amp; 28 of each cycle: duration of treatment phase</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Euro-QoL Visual Analog Scale (EQ-VAS)</outcome>
      <timepoint>Day 1 &amp; 28 of each cycle: duration of treatment phase</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Concentrations of Soluble Proteins: Plasma VEGF-A, Plasma VEGF-C, Plasma sVEGFR-3, PLASMA IL-8, and PLASMA bFGF That May be Associated With Tumor Proliferation or Angiogenesis</outcome>
      <timepoint>Day 1 &amp; Day 28, Cycle 1 to Cycle 4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Concentrations of Soluble Proteins: Plasma Basic Fibroblast Growth Factor (bFGF) That May be Associated With Tumor Proliferation or Angiogenesis</outcome>
      <timepoint>Day 1 &amp; Day 28, Cycle 1 to Cycle 4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incremental Cost Effectiveness Ratio (ICER)</outcome>
      <timepoint>post study measurement</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ctrough Concentrations of SU011248</outcome>
      <timepoint>Day 28 of Cycle 1 to Cycle 4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ctrough Concentrations of Metabolite SU012662</outcome>
      <timepoint>Day 28 of Cycle 1 to Cycle 4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ctrough Concentrations of SU011248 and Active Metabolite SU012662</outcome>
      <timepoint>Day 28 of Cycle 1 to Cycle 4</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histologically confirmed renal cell carcinoma of clear cell histology with metastases

          -  Evidence of measurable disease by radiographic technique

          -  Eastern Cooperative Oncology Group [ECOG] performance status of 0 or 1</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior systemic (including adjuvant or neoadjuvant) therapy of any kind for RCC

          -  History of or known brain metastases

          -  Serious acute or chronic illness or recent history of significant cardiac abnormality</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>750</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Pfizer Investigational Site - Lismore</hospital>
    <hospital>Pfizer Investigational Site - St. Leonards</hospital>
    <hospital>Pfizer Investigational Site - South Brisbane</hospital>
    <hospital>Pfizer Investigational Site - Woodville South</hospital>
    <hospital>Pfizer Investigational Site - East Melbourne</hospital>
    <hospital>Pfizer Investigational Site - Perth</hospital>
    <hospital>Pfizer Investigational Site - Victoria</hospital>
    <postcode>2480 - Lismore</postcode>
    <postcode>2065 - St. Leonards</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <postcode>5011 - Woodville South</postcode>
    <postcode>3002 - East Melbourne</postcode>
    <postcode>6000 - Perth</postcode>
    <postcode>36184 - Victoria</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>RJ</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>RS</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Cedex 15</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 13</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rennes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint Herblain</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre Les Nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Aachen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ulm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Modena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Napoli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pavia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kaluga Region</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Chelyabinsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint-Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Tomsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Navarra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cardiff</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Lancashire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Middlesex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sutton Surrey</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to test whether SU011248 has activity and is safe compared to
      interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00083889</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>